Supernus Pharmaceuticals, Inc.SUPNNASDAQ
Loading
EBITDA Margin Over TimeContracting
Percentile Rank29
3Y CAGR-14.0%
5Y CAGR-18.4%
Year-over-Year Change
EBITDA as a percentage of revenue
3Y CAGR
-14.0%/yr
vs -11.3%/yr prior
5Y CAGR
-18.4%/yr
Recent acceleration
Acceleration
-2.8pp
Decelerating
Percentile
P29
Within normal range
vs 5Y Ago
0.4x
Contraction
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| TTM | 14.60% | -45.8% |
| 2024 | 26.94% | +81.8% |
| 2023 | 14.82% | -35.5% |
| 2022 | 22.98% | +3.1% |
| 2021 | 22.28% | -44.9% |
| 2020 | 40.46% | -11.9% |
| 2019 | 45.94% | +24.0% |
| 2018 | 37.05% | +4.0% |
| 2017 | 35.63% | +35.3% |
| 2016 | 26.33% | - |